KR890017246A - 크로만 유도체 - Google Patents

크로만 유도체 Download PDF

Info

Publication number
KR890017246A
KR890017246A KR1019890006017A KR890006017A KR890017246A KR 890017246 A KR890017246 A KR 890017246A KR 1019890006017 A KR1019890006017 A KR 1019890006017A KR 890006017 A KR890006017 A KR 890006017A KR 890017246 A KR890017246 A KR 890017246A
Authority
KR
South Korea
Prior art keywords
oxy
formula
chroman
cyano
trimethyl
Prior art date
Application number
KR1019890006017A
Other languages
English (en)
Other versions
KR0150781B1 (ko
Inventor
케리케 랄프
바움가르드 맨프레트
루에스 인게보르그
베르그만 랄프
드 페이어 자퀴스
Original Assignee
나우만, 호이만
메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프둥
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE3815504A external-priority patent/DE3815504A1/de
Priority claimed from DE3835011A external-priority patent/DE3835011A1/de
Application filed by 나우만, 호이만, 메르크 파텐트 게젤샤프트 미트 베슈랭크터 하프둥 filed Critical 나우만, 호이만
Publication of KR890017246A publication Critical patent/KR890017246A/ko
Application granted granted Critical
Publication of KR0150781B1 publication Critical patent/KR0150781B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

내용 없음

Description

크로만 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(I)의 크로만 유도체 및 그의 염.
    상기식에서 R1과 R8는 각각 A이고, R2는 H 또는 A이고, R1과 R2는 모두 3-6 탄소원자를 지닌 알킬렌이고, R3는 OH 또는 OAc이고, R4는 수소이고, R3와 R4는 각각 결합이고, R5는 A, F, Cl, Br, J, OH, OA, OAc, NO2, NH2, AcNH, HOOC 및/또는 AOOC가 하나 또는 둘 치환되어 있거나 치환되지 않은 피리딜-옥시, 피리다진일-옥시, 피리미딘일-옥시, 피라진일-옥시, 옥시-디히드로-피리닐-옥시, 옥소-디히드로-피라다진일-옥시, 옥소-디히드로-피리미딘일-옥시, 옥소-디히드로-피라진일-옥시, 1H-2-피리돈-1-일, 1H-6-피리다진온-1-일, 1H-2-피리미딘온-1-일, 1H-6-피리미딘온-1-일, 1H-2-피라진온-1-일, 3H- 또는 5H-2-피롤린온-1-일 또는 1H-2-티오피리돈-1-일 등의 치환기를 말하면 이들은 전체적 또는 부분적으로 수소화 되어 있다. R6와 R7은 각각 H, A, HO, AO, CHO, ACO, ACS, HOOC, AOOC, AO-CS, ACOO, A-CS-O, 1-6탄소원자를 지닌 히드록시알킬, 1-6 탄소원자를 지닌 머르캅토알킬, NO2,NH2,NHA,NA2,CN,F,Cl,Br,I,CF3,ASO,ASO2AOSO,AOSO2,AcNH,AOCONH,H2NSO,HANSO,A2NSO,H2NSO2,HANSO2,A2NSO2,H2NCO,HANCO,A2NCO,H2NCS,HANCS,A2NCS,ASONH,ASO2NH,AOSONH,AOSO2NH,ACO-알킬, 니트로알킬, 시아노일킬, A-C(=NOH) 또는 A-C(=NNH2)이고, A는 1-6 탄소원자를 지닌 알킬이고, 알킬은 1-6 탄소원자를 지닌 알킬렌이고, Ac는 1-8 탄소원자를 지닌 알칸오일 또는 7-11 탄소원자를 지닌 아로일이다.
  2. a) 2,2,3-트리메틸-4-(1H-2-피리돈-1-일)-6-시아노-크로만-3-올. b) 2,2,3-트리메틸-4-(1H-2-피리돈-1-일)-6-시아노-2H-크로만. c) 2,2,3-트리메틸-4-(2-히드록시-피라딜-옥시)-6-시아노-크로만-3-올. d) 2,2,3-트리메틸-4-(6-히드록시-3-피리다진일-옥시)-6-시아노-크로만-3-올. e) 2,2,3-트리메틸-4-(1,5-디히드로-1메틸-6-옥소-3-피리다진일-옥시)-6-시아노-크로만-3-올. f) 2,2,3-트리메틸-4-(1,6-디히드로-1-에틸-6-옥소-3-피리다진일-옥시)-6-시아노-크로만-3-올. g) 2,2,3-트리메틸-4-(2-피롤리돈-1-일)-6-옥소-3-피리다진일-옥시)-6-시아노-크로만-3-올. h) 2,2,3-트리메틸-4-(2-피롤리돈-1일)-6-옥소-3-피리다진-일-옥시)-6-시아노-2H-크로만.
  3. 일반식(Ⅱ)의 3,4-에폭시크로만을 일반식(Ⅱ)의 화합물 또는 이의 반응성 유도체중 하나와 반응시키고/시키거나 R3가 OH이고 R4가 수소인 일반식(I)의 화합물을 탈수하고/하거나, 일반식(I)에 있어서 R3,R5,R6및/또는 R7의 치환기중 하나 이상을 다른 R3,R5,R6및/또는 R7의 치환기로 전환 시키고/시키거나, 일반식(I)의 염기성 화합물을 산으로 처리하여 그의 산부가염증 하나로 전환시킴을 특징으로 하는 일반식(I)의 크로만 유도체의 제조방법.
    상기식에서 R5,R6,R7및 R8은 제1항의 주어진 의미와 같다.
  4. 일반식(I)의 화합물 및/또는 그의 생리학적으로 허용될 수 있는 염을 투여에 적합하도록 적어도 하나 이상의 고형, 액체형 또는 반고형의 부형제 또는 보호제와 혼합하거나 하나 이상의 다른 활성 화합물과 혼합물을 특징으로 하는 약제학적 제제의 제조방법.
  5. 적어도 하나 이상의 일반식(I)의 화합물 및/또는 그의 생리학적으로 허용될 수 있는 염을 포함하는 약제학적 제제.
  6. 질병 치료용으로서의 일반식(I)의 화합물.
  7. 일반식(I)의 화합물의 의약제조용으로의 용도.
  8. 일반식(I)의 화합물의 질병치료 용도.
  9. 일반식(Ⅳ)의 화합물.
    상기식에서, -X,Y-은 (a) -CO-CH2-, (b) -CO-CR10, (c) -CHOH-CHR8-, (d) -CH=CR8- (e)이고, R9는 CHO,ACO,AOOC,NO2,CN,Br,H2NCO 또는 NSS이고 R10은 탄소수 1-6의 알킬디엔이고, R1과 R2는 제1항의 주어진 바와 같다.
  10. a) 2,2-디메틸-6-시아노-크로만-4-온. b) 2,2,3-트리메틸-3,4-에폭시-시아노-크로만.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890006017A 1988-05-06 1989-05-04 크로만 유도체 KR0150781B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE3815504A DE3815504A1 (de) 1988-05-06 1988-05-06 4-n-heterocyclyl-chromanderivate, verfahren sowie zwischenprodukte zu ihrer herstellung und ihre verwendung in arzneimitteln
DEP3815504.4 1988-05-06
DE3835011A DE3835011A1 (de) 1988-10-14 1988-10-14 Chromanderivate
DEP3835011.4 1988-10-14

Publications (2)

Publication Number Publication Date
KR890017246A true KR890017246A (ko) 1989-12-15
KR0150781B1 KR0150781B1 (ko) 1998-10-15

Family

ID=25867854

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890006017A KR0150781B1 (ko) 1988-05-06 1989-05-04 크로만 유도체

Country Status (17)

Country Link
US (1) US5013853A (ko)
EP (1) EP0340718B1 (ko)
JP (1) JPH01319481A (ko)
KR (1) KR0150781B1 (ko)
AR (1) AR246966A1 (ko)
AT (1) ATE108786T1 (ko)
AU (1) AU628331B2 (ko)
DE (1) DE58908062D1 (ko)
DK (1) DK223289A (ko)
ES (1) ES2057010T3 (ko)
FI (1) FI93358C (ko)
HU (1) HU207311B (ko)
IE (1) IE63794B1 (ko)
IL (1) IL90198A (ko)
NO (1) NO174467C (ko)
NZ (1) NZ228991A (ko)
PT (1) PT90471B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
DE3835011A1 (de) * 1988-10-14 1990-04-19 Merck Patent Gmbh Chromanderivate
US5284838A (en) * 1987-06-23 1994-02-08 Elf Sanofi Use of 2,2-dimethylchroman-3-ol derivatives in the treatment of asthma
WO1989010925A1 (en) * 1988-05-09 1989-11-16 Beecham Group Plc Novel compounds and treatment
EP0346724A1 (de) * 1988-06-16 1989-12-20 MERCK PATENT GmbH Chromanderivate
DE3918041A1 (de) * 1989-06-02 1990-12-06 Merck Patent Gmbh Chromanderivate
DE3923839A1 (de) * 1989-07-19 1991-01-31 Beiersdorf Ag Benzopyran-derivate, verfahren zu ihrer herstellung und ihre verwendung sowie die verbindungen enthaltende zubereitungen
US5223629A (en) * 1989-07-21 1993-06-29 Alkaloida Vegyeszeti Gyar Process for the preparation of anti-hypertensive benzopyran
DE3924417A1 (de) * 1989-07-24 1991-01-31 Merck Patent Gmbh Chromanderivate
DE3936616A1 (de) * 1989-11-03 1991-05-08 Merck Patent Gmbh Verfahren zur enantiomerentrennung von benzopyranderivaten
DE4038752A1 (de) * 1990-12-05 1992-06-11 Merck Patent Gmbh Chromanderivate
NZ240933A (en) * 1990-12-21 1993-05-26 Ortho Pharma Corp Preparing enantiomerically pure thienopyran derivatives
US5332168A (en) * 1991-04-01 1994-07-26 Fuji Photo Film Co., Ltd. Photographic film cassette with improved separator claw
JP3442815B2 (ja) * 1992-05-13 2003-09-02 第一製薬株式会社 ジアザビシクロアルケン誘導体
US5527534A (en) * 1992-10-21 1996-06-18 Gynetech Laboratories, Ltd. Vaginal sponge delivery system
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
US5719155A (en) * 1993-11-10 1998-02-17 Japan Tobacco Inc. Chroman derivative and pharmaceutical use thereof
US5612370A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
US5629429A (en) * 1995-06-07 1997-05-13 Bristol-Myers Squibb Company Process for preparing 4-arylamino-benzopyran and related compounds
US5612323A (en) * 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phosphinic ester substituted benzopyran derivatives
US5869478A (en) * 1995-06-07 1999-02-09 Bristol-Myers Squibb Company Sulfonamido substituted benzopyran derivatives
EP1218367A1 (en) * 1999-10-05 2002-07-03 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
FR2820974B1 (fr) * 2001-02-21 2004-02-13 Pharmascience Lab Composition topique comprenant une solution vraie contenant un derive de chromane ou de chromene, son procede de preparation et son utilisation cosmetique et therapeutique
BRPI0519013A2 (pt) * 2004-12-13 2009-11-03 Lilly Co Eli composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto
US10981951B2 (en) 2014-01-31 2021-04-20 Mayo Foundation For Medical Education And Research Therapeutics for the treatment of glaucoma

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1077066A (en) * 1963-09-10 1967-07-26 Benger Lab Ltd Improvements in or relating to the synthesis of chromanones
US3467676A (en) * 1967-04-05 1969-09-16 American Home Prod 5-hydroxy-2,2,7-trialkylchroman-4-ones and derivatives
CH619701A5 (ko) * 1975-08-07 1980-10-15 Bayer Ag
DE2745305A1 (de) * 1977-10-07 1979-04-19 Bayer Ag Insektizide und akarizide mittel
DE2814983A1 (de) * 1978-04-07 1979-10-18 Bayer Ag Neue chromanon-derivate
JPS6047269B2 (ja) * 1978-04-14 1985-10-21 日産化学工業株式会社 クロマノ−ル類化合物およびその製造方法
US4241069A (en) * 1979-09-04 1980-12-23 Miles Laboratories, Inc. 3-Methylene flavanones and 3-methylene chromanones
DE3274350D1 (en) * 1981-09-25 1987-01-08 Beecham Group Plc Pharmaceutically active benzopyran compounds
US4486428A (en) * 1982-03-16 1984-12-04 Pfizer Inc. Bicyclic benzo fused compounds
DE3368629D1 (en) * 1982-04-28 1987-02-05 Beecham Group Plc Novel chromenes and chromans
EP0107423B1 (en) * 1982-10-19 1986-07-23 Beecham Group Plc Novel chromans and chromenes
JPS6016983A (ja) * 1983-07-08 1985-01-28 Daicel Chem Ind Ltd ３−メチレン−４−クロマノン誘導体
HU194855B (en) * 1983-02-16 1988-03-28 Alkaloida Vegyeszeti Gyar Process for producing chromene derivatives, insecticide and nematocide compositions containing chromene derivatives as active components
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
DE3475786D1 (de) * 1983-09-01 1989-02-02 Beecham Group Plc Chromanol derivatives
US4777168A (en) * 1984-10-23 1988-10-11 Rorer Pharmaceutical Corporation Bicyclic benzo-oxy heterocyclic ethers and thioethers, pharmaceutical compositions and use
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
DE3835011A1 (de) * 1988-10-14 1990-04-19 Merck Patent Gmbh Chromanderivate
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
FR2615191B1 (fr) * 1987-05-16 1991-01-11 Sandoz Sa Nouveaux benzo(b)pyrannes et pyrannopyridines, leur preparation et leur utilisation comme medicaments
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
EP0346724A1 (de) * 1988-06-16 1989-12-20 MERCK PATENT GmbH Chromanderivate

Also Published As

Publication number Publication date
IL90198A (en) 1994-01-25
DK223289D0 (da) 1989-05-05
DE58908062D1 (de) 1994-08-25
PT90471B (pt) 1994-09-30
NO891866D0 (no) 1989-05-05
FI93358B (fi) 1994-12-15
US5013853A (en) 1991-05-07
IE891474L (en) 1989-11-06
FI93358C (fi) 1995-03-27
JPH01319481A (ja) 1989-12-25
HU207311B (en) 1993-03-29
HUT56094A (en) 1991-07-29
FI892182A (fi) 1989-11-07
NZ228991A (en) 1990-12-21
NO174467B (no) 1994-01-31
ATE108786T1 (de) 1994-08-15
NO174467C (no) 1994-05-11
IL90198A0 (en) 1989-12-15
AR246966A1 (es) 1994-10-31
AU3390189A (en) 1989-11-09
IE63794B1 (en) 1995-06-14
KR0150781B1 (ko) 1998-10-15
AU628331B2 (en) 1992-09-17
NO891866L (no) 1989-11-07
EP0340718B1 (de) 1994-07-20
EP0340718A1 (de) 1989-11-08
DK223289A (da) 1989-11-07
FI892182A0 (fi) 1989-05-05
ES2057010T3 (es) 1994-10-16
PT90471A (pt) 1989-11-30

Similar Documents

Publication Publication Date Title
KR890017246A (ko) 크로만 유도체
KR880007507A (ko) 크로만 유도체
DE69328192T4 (de) Injizierbare Arzneizubereitungen enthaltend Taxanderivate
KR900007837A (ko) 퀴누클리딘, 약제로서 이의 용도 및 이의 제조방법
HUT43786A (en) Process for production of medical compounds with increased giving down of the active substance
KR890002060A (ko) 옥사졸리디논 화합물
KR930021143A (ko) 안정한 포르피머 나트륨 조성물 및 그의 제조방법
DK130883D0 (da) Fremgangsmade til fremstilling af terapeutiske eller diagnostiske praeparater
ATE1814T1 (de) 9-hydroxyalkylpurine, verfahren zu ihrer herstellung und 9-hydroxyalkylpurine als aktive mittel enthaltende therapeutische zusammensetzung.
DE69328575T2 (de) Dermatologische Präparate
KR910000711A (ko) 크로만 유도체
DE2322232A1 (de) Neue acylaminosaeureamide
KR910000713A (ko) 크로만 유도체
KR900006326A (ko) 크로만 유도체
KR900007798A (ko) 테트랄린 유도체
KR910004602A (ko) 크로만 유도체
KR910002842A (ko) 크로만 유도체
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR880002518A (ko) 소염제 조성물
EP0324745B1 (de) Prostacyclinderivate enthaltende mittel für die topische anwendung
KR890005113A (ko) 아자크로만 유도체
DE69711920D1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
KR910002456A (ko) 당뇨병 치료용 제약 조성물
FR2677650B1 (fr) Retinouides substitues par un cycle dithiane et leur utilisation, procede de preparation desdits composes, compositions cosmetique et pharmaceutique les contenant et utilisation therapeutique de cette derniere.
KR880013562A (ko) 7-티아프로스타글란딘e₁ 또는 그의 유도체를 함유하는 당뇨병치료 조성물

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee